

Meeting: WAO Symposium on Immunotherapy & Biologics
Biologics Track 4: Critical Novel Molecules for Allergic Diseases [Dec 14 (Saturday) @ 8-9:30 am]
Lecture: Advances in Synthetic Peptide Immuno-Regulatory Epitopes
Speaker: Peter Socrates Creticos, M.D.
Re: Handout

A) Pertinent Studies with T Cell-tolerizing Peptide Immunotherapy // Synthetic Peptide Immuno-Regulatory Epitopes

1. Briner T, Kuo M, Keating K, Rogers B. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d 1. *Proc Natl Acad Sci USA* 1993; 90:7608-12. [basic science]
2. Wallner B, Geftner M. Immunotherapy with T-cell-reactive peptides derived from allergens. *Allergy* 1994; 49:302-308. [basic science]
3. Norman P, Ohman J, Long A, Creticos P, et al. Treatment of cat allergy with T-cell reactive peptides. *Am J Respir Crit Care Med* 1996; 154: 1623-28. [clinical trial]
4. Norman PS, Nicodemus C, Creticos PS, et al. Clinical and immunologic effects of component peptides in Allervax Cat. *Int Arch Allergy Immunol* 1997; 113:1-3. [review]
5. Varney V, Edwards J, Tabbah K, et al. Clinical Efficacy of specific immunotherapy to cat dander; a double-blind placebo-controlled trial. *Clin Exp Allergy* 1997; 27:860-67. (non-peptide; cx reference)
6. Creticos PS, Herbert J, Philip G; The Allervax Ragweed Study Group. Efficacy of Allervax ragweed in the treatment of ragweed-induced allergy. *J. Allergy Clin Immunol* 1997; 99 (1 Pt 2): S401; 1631. [abstract]
7. Creticos PS. Peptide Downregulation of the Immune Response. *Asthma and Allergic Diseases*. Academic Press 1998; Chapter 30: 407-415. (Editors: Gianni Marone, K. Frank Austen, Stephen T. Holgate, A. Barry Kay, Lawrence M. Lichtenstein). [book chapter]
8. Oldfield W, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. *Lancet* 2002; 360: 47-53. [clinical trial]
9. Fellrath JM, Kettner A, Dufour N, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. *J Allergy Clin Immunol* 2003; 111:854-61. [clinical trial]
10. Smith T, Alexander C, Kay AB, et al. Cat allergen peptide immunotherapy reduces CD4 T cell responses to cat allergen but does not alter suppression by CD4 CD25 T cells: a double-blind placebo-controlled study. *Allergy* 2004; 59: 1097-1101. [mechanistic]
11. Alexander C, Ying S, Kay AB, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ IFN-gamma + T helper type 1 cells to sites of allergen-induced late-phase skin test reactions in cat-allergic subjects. *Clin Exp Allergy* 2005; 35:52-58. [mechanistic]
12. Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. *Allergy* 2005; 60:1269-74. [clinical trial]
13. Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4(+) T cell population with regulatory activity. *PLoS Med* 2005; 2:e78. [mechanistic]

14. Campbell J, Buckland K, McMillan S, et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. *JEM* 2009; 206: 1535. [mechanistic]
 15. Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. *J Allergy Clin Immunol* 2011; 127 (1):89-97. [clinical trial]
 16. Patel D, Couroux P, Hickey P, Salapatek A, Laidler P, Larche M, Hafner R. Fel d 1-derived peptide antigen desensitization shows a persistent treatment Effect 1 year after the start of dosing: A randomized, placebo-controlled study. *J Allergy Clin Immunol* 2013; 131(1): 103-109. [clinical trial]
 17. Moldaver D, Bharhani M, Wattie J, Hafner R, et al. Suppression of Allergic Airway Inflammation by Low Dose, Intranasally Administered Der p 1 Derived Peptides, in a Murine Model of House Dust Mite Allergy. *J Allergy Clin Immunol* 2012; Vol. 129, Issue 2, Supplement, Page AB241 (abstract).
 18. Haumann B, Powell J, Hafner R. Safety and Tolerability of Fel d 1-Derived Peptide Antigen Desensitization. *J Allergy Clin Immunol* 2013; Vol. 131, Issue 2, Supplement, Page AB38 (abstract).
 19. Pascal L, Hickey P, Singh A, et al. Safety and Tolerability of Fel d 1-Derived Peptide Antigen Desensitization in Subjects with Controlled Asthma. *J Allergy Clin Immunol* 2013. Vol. 131, Issue 2, Supplement, Page AB206 (abstract).
 20. Larché M, Hickey P, Hebert J, Hafner R. Safety and Tolerability of Escalating Doses of House Dust Mite- Peptide Antigen Desensitization (HDM-PAD). *J Allergy Clin Immunol* 2013; Vol. 131, Issue 2, Supplement, Page AB37 (abstract).
 21. Hafner R, Couroux P, Armstrong K, Patel D, et al. Two Year Persistent Treatment Effect Achieved After 4 Doses of Cat-Peptide Antigen Desensitization (Cat-PAD) in an Environmental Exposure Chamber (EEC) Model of Cat Allergy. *J Allergy Clin Immunol* 2013; Vol. 131, Issue 2, Supplement, Page AB147 (abstract).
 22. Haumann B, Couroux P, Armstrong K, Patel D, Larché M, Hafner R. Cat-PAD demonstrates sustained, consistent treatment effect on allergic rhinoconjunctivitis in individual cat-allergic patients 1 and 2 years after 4 intradermal injections. *EAACI-WAO 2013; Allergy*, 68: 1–104 (abstract).
 23. Powell J, Haumann B, Hafner R. Cat-PAD, the first in a new class of synthetic peptide immunoregulatory epitopes, demonstrates a favourable tolerability profile in patients with cat-induced rhinoconjunctivitis. *EAACI-WAO 2013; Allergy*, 68: 115–188 (abstract).
-